Summary The results of preclinical and clinical studies indicate enhanced antineoplastic activity of topotecan (SKF 104864-A) when administered as a chronic treatment. We determined the apparent bioavailability and pharmacokinetics of topotecan administered orally to 12 patients with solid tumours in a two-part crossover study. The oral dose of 1.5 mg m 2 was administered as a drinking solution of 200 ml on day 1. The i.v. dose of 1.5 mg m-2 was administered as a 30 min continuous infusion on day 2. The bioavailability was calculated as the ratio of the oral to i.v. area under the curve (AUC) calculated up to the last measured time point. The oral drinking solution was well tolerated. The bioavailability revealed moderate inter-patient variation and was 30%+7.7% (range 21-45%). The time to maximum plasma concentration after oral administration (Tmax) was 0.78 h (median; range 0.33-2.5). Total i.v. plasma clearance of topotecan was 824+ 154 ml min-' (range 535-1068 ml min-'). The AUC ratio of topotecan and the lactone ring-opened hydrolysis product (hydroxy acid) was of the same order after oral (0.34-1.13) and i.v. (0.47-0.98) administration. The bioavailability of topotecan after oral administration illustrates significant systemic exposure to the drug which may enable chronic oral treatment.
Topotecan (SKF 104864) [(S)-9-dimethylaminomethyl-10-hydroxycamptothecin hydrochloride] is a semisynthetic water-soluble analogue of camptothecin (Hsiang and Liu, 1988) . Like camptothecin, topotecan is a specific inhibitor of topoisomerase I (Hsiang and Liu, 1988) . Topotecan incorporates a stable basic side-chain at the 9-position of the A-ring, which provides water solubility at acid pH. Topotecan is converted to its lactone ring-opened hydrolysis product (hydroxy acid), which reversible pathway is strongly pH dependent. The biological activity of the hydroxy acid has not been fully elucidated (Kingsbury et al., 1991) . Antitumour activity has been demonstrated in preclinical models and in phase I and II studies Rowinsky et al., 1992; Wall et al., 1992; Blaney et al., 1993; Hochster et al., 1994; Verweij et al., 1993; Creemers et al., 1994 for review) . The results of preclinical and clinical studies indicate enhanced antineoplastic activity of topotecan when administered daily for prolonged periods of time (Giovanella et al., 1989; Burris et al., 1992; Houghton et al., 1992; Rowinsky et al., 1992; Hochster et al., 1994; Verweij et al., 1993) . Also, preclinical studies with oral topotecan have shown that it has efficacy against rhabdomyosarcoma and colon carcinoma in mice (Houghton et al., 1992) . The unique mechanism of action and lack of cross-resistance evidence with many wellknown currently available anti-tumour agents may provide therapeutic advantage in first-line or second-line chemotherapy. Furthermore, combination therapy of topotecan and other available antineoplastic agents may well be advantageous (Miller et al., 1993; Rothenberg et al., 1993) . In view of the data suggesting the importance of prolonged exposure to topotecan for better anti-tumour activity and the impracticality of achieving this exposure by intravenous administration, an oral formulation is being developed.
In the present study the bioavailability and pharmacokinetics of oral topotecan are explored in patients with solid tumours with the aim of providing a basis for further development of clinical studies using chronic oral topotecan.
Patient selection, materials and methods Patient selection and treatment schedule All patients gave written informed consent according to local regulatory requirements. Eligibility for the clinical study required a pathologically confirmed small-cell lung cancer, colon cancer or ovarian cancer refractory to standard therapy or for which cancer type no therapy of proven benefit exists. The performance status had to be < 2 on the WHO scale and life expectancy >3 months. The minimum age was 18 and maximum age 75 years. The haemoglobulin had to be >6.0 mmol 1 -1 (9 g dl-'), WBC. 3500 ul-', granulocytes , 1000 l-d and platelets >100 000 jil-'. The serum creatinine had to be < 140 imol 1-1 (1.6 mg dl-'), the serum bilirubin <26 ,umol 1`( 1.5 mg dl-') and alkaline phosphatase and transaminases <2 times the upper normal limit if liver metastases were absent or -5 times the upper normal limit if liver metastases were present.
Topotecan was administered orally and intravenously at a dose of 1.5 mg m-2. Topotecan as supplied for intravenous infusion was diluted for oral dosage. Each 5 mg vial of topotecan was reconstituted with 10 ml of 5% dextrose injection solution to give a 0.5 mg ml-' solution of the drug. The dose was placed in a beaker containing 100 ml of 5% dextrose injection solution. On day 1, patients were asked to drink the entire contents. Subsequently, an additional 100 ml of 5% dextrose injection solution was added to the beaker and taken by the patient. On day 2 topotecan was administered at the same dose as a continuous 30 min intravenous infusion. The 5 mg vials of topotecan were reconstituted in 5% dextrose and the appropriate volume was then added to a volume of 50 ml of 5% dextrose. The drug was given at approximately the same time of day, between 08.00 and 11.00 h. On both days of drug administration the patients were fasted for 4 h before the time schedule for dosing. Fasting continued for a further 2 h after drug administration on both days. Fluid intake was not restricted.
Blood sample collection Serial heparinised blood samples (2.8 ml) were collected on both days of drug administration through an indwelling intravenous cannula that was inserted in the arm contraCorrespondence: JHM Schellens Received 24 July 1995; revised 11 December 1995; accepted 12 December 1995 lateral to that which was used for the infusion. Blood samples were taken at 0, 10, 20, 30 and 45 min and 1, 1.5, 2.5, 3.5, 4.5, 6.5 and 8.5 h after start of drug administration. After collection, the blood samples were centrifuged immediately for 5 min at 3500 r.p.m. One millilitre of the plasma was immediately transferred to a polypropylene tube containing 4 ml of cold methanol (-20°C) 
Assay of topotecan and hydroxy acid
Topotecan and the hydroxy acid were analysed simultaneously with an automated reversed-phase HPLC system and fluorescence detection as described by Beijnen et al. (1990) , with modifications to reduce the lower limit of quantitation (LLQ) (Loos et al., 1996) . The LLQ was 0.1 ng ml 'for topotecan as well as for the hydroxy acid. Data were accepted if the deviation from the nominal value of the individual calibration samples and quality controls was <15% (20% at the LLQ).
Pharmacokinetic analysis
The areas under the plasma concentration -time curves (AUC) of topotecan and hydroxy acid were calculated with compartmental and non-compartmental analysis using the Siphar software package release 4.0 (Siphar SIMED, Creteil, France). The trapezoidal method was used for the noncompartmental analysis. The AUC(t) was calculated up to the latest measured time point. The total AUC (AUCoo) was calculated after extrapolation of the curve to infinity where appropriate using the terminal elimination rate constant k. The apparent bioavailability was calculated as the ratio of the AUC(t) after oral and i.v. administration. All concentrationtime profiles were fitted using the extended least squares method (LSM) (Sheiner and Beal, 1985) . The volume of distribution at steady state (Vd,ss) and total plasma clearance (Cl=dose/AUC) were calculated after i.v. administration of topotecan using the AUC extrapolated to infinity (AUCoo).
The terminal half-life (tl/2) was calculated after oral and i.v. administration as ln2/k.
Visual inspection of the concentration-time curves, the objective function and the Akaike information criterion (Yamaoka et al., 1978) were applied to choose the optimal model for quantitation of the AUC.
Statistical analysis
The Pearson correlation coefficient was calculated between the ratio of the AUC(t) of the hydroxy acid and topotecan after oral and i.v. administration and between the ratio of the AUC(t) of the hydroxy acid after oral and i.v. administration and the bioavailability. Two-sided paired and unpaired t-tests were applied to determine any significant difference between the half-lives of topotecan and hydroxy acid after oral and i.v. administration. profiles of topotecan could be fitted well (r>0.97) applying LSM and the outlined models. In ten patients the model using a two-exponential decline of the concentration -time curve resulted in the highest correlation coefficient and lowest Akaike value. In one patient the model with a threeexponential decline of the curve and in one other patient a one-exponential decline resulted in the best fit. In most patients the curves of the hydroxy acid could not be fitted properly using extended LSM, assuming linear pharmacokinetics. The plasma concentration -time curves of the hydroxy acid were higher than those of topotecan in all patients. The pharmacokinetic data are summarised in Tables I and II. After oral administration the per cent of the AUC extrapolated in eight patients was > 20%, therefore the bioavailability was calculated using the ratio of AUC(t) instead of the AUC extrapolated to infinity (AUCoo). The mean + s.d. of the AUC(t) of topotecan after oral administration was 15.18+5.51 ng h-' ml-' (range 9.38-25.37 ng h-' ml-'; Table I). The AUC(t) of topotecan after i.v. administration was 49.87+ 10.87 ng h-'ml-' (range 32.50 -73.68 ng h-'ml-'). The AUCoo of topotecan after i..v. administration was 61.02 + 10.57 ng h ' ml-(range 43.70 -81.08 ng h ' ml-'). The bioavailability was 30% + 7.7% (range 21% -45%). The coefficient of variation (CV) was 25.4%. If the curves had been extrapolated to infinity, then the bioavailability would have been calculated as 32% + 11.5%.
The median of the Tmax was 0.78 h and the range 0.33-2.5 h. The half-life for the initial decline of the plasma concentration -time curve (t1/2 .) after i.v. administration was 0.186+0.054 h based on the data for the ten patients that were fitted with a biexponential model. (Hochster et al., 1994) . It would increase the xy acid.
convenience for the patient substantially if the drug on a chronic treatment schedule could be taken orally.
The apparent bioavailability was determined in 12 patients tecan and the hydroxy with various types of solid tumours. The bioavailability + 0.25 (n = 9) and after ranged from 21% to 45%. The term apparent bioavailability rrelation coefficient was has been used because topotecan undergoes a reversible, pH->(t) of the hydroxy acid dependent conversion to the hydroxy acid at physiological vas 0.38 + 0.12 (n = 9), pH and the standard equation for the calculation of the bioavailability of bioavailability no longer applies. The correct equations between this ratio and contain terms for the AUC of topotecan, and hydroxy acid after i.v. administration of the hydroxy acid itself. The iship between age or standard equation for bioavailability, as used in this study, is lition, there was no a function not only of dose and input rate, but also of le presence of liver conversion clearance. The accuracy of the apparent bioavailbioavailability. ability data will depend, to a large extent, on the magnitude oral administration was of the conversion clearance, for which no in vivo data on ng ml-1) and after i. 
(ng mr') (ng mr') (ng h-ml-) (ng h-1 mr') (ng h-' mr') (%) (ng h-1 ml-) (ng h-1 ml-) 1271 because there is no carryover of topotecan into the second treatment period. In addition, topotecan is not metabolised and therefore cannot induce its own elimination. Plasma samples were collected up to 8 h after oral administration. This was slightly too short to extrapolate the AUC up to infinity. The sampling time was determined based on preclinical data on the oral administration in dogs and on the elimination pharmacokinetics after i.v. administration in man. The bioavailability after oral administration in dogs was 35.7% + 16.3% (unpublished data), which is close to the result obtained in patients. The calculation of the bioavailability using the AUCoo resulted in only a marginally higher value of 32% instead of 30%. Apparently, the applied ratio of AUC(t) gives a good estimate of the bioavailability.
The t1/2 fl in the patient with the highest bioavailability of 45% was 1.8 h after i.v. and 3.2 h after oral administration. This difference was relatively large in comparison with the data obtained in the other patients. This patient had a large tumour in the upper part of the abdomen. It cannot be excluded that this extensive tumour mass has influenced the rate of passage of topotecan through the gastrointestinal tract and thereby the magnitude of the absorption. The Tmax of this patient was 2.5 h, which is delayed compared with the range of the other 11 patients (0.33 -1.5 h).
The CV of the AUC(t) after oral administration was 36.6% and after i.v. administration 21.8%. Hence, oral administration increased the interpatient difference in systemic exposure markedly. It has to be elucidated in follow-up studies whether this variation has clinical implications. In addition, the intra-patient variability needs to be determined in future studies.
The CV of the plasma clearance of topotecan after i.v. administration was 18.8%. The range of the data was of the same order as reported by Rowinsky et al. (1992) and Verweij et al. (1993) .
No relationships were found between patient characteristics such as age, gender, performance score and the bioavailability. In addition, the presence of liver metastases or concomitant drugs did not seem to be related to the magnitude of the bioavailability.
The ratio of topotecan and hydroxy acid was of the same order after oral and i.v. administration. There would appear only two reasonable explanations for the observed data: either topotecan is poorly absorbed from the gastrointestinal tract or topotecan is well absorbed but a large part of the dose is converted presystemically in the gut into the hydroxy acid, which is itself not absorbed to any appreciable extent. The good water solubility of topotecan coupled with the rapid absorption would suggest that the second explanation can best describe the data obtained in this study. There is no evidence for the formation of other metabolites that may explain the observed data.
The bioavailability of topotecan after oral administration illustrates significant systemic exposure to the drug which may enable chronic oral treatment.
